A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation

Journal of Clinical Psychopharmacology

Volumn 14, Issue 6, 1994, Pages 377-384

  Chouinard, Guy ^a,b   Safadi, Gabriel ^a,c   Beauclair, Linda ^a,b  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b Allan Memorial Institute   (Canada)

^c HÔPITAL CHARLES LEMOYNE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPENTHIXOL; FLUPENTIXOL DECANOATE; HALOPERIDOL; PROCYCLIDINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TREMOR;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AROUSAL; CLOPENTHIXOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0028135118     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199412000-00002     Document Type: Article

References (41)

1. Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta Psychiatr Scand 1980;61(suppl 279):77–91.
2. Carney MWP, Rutherford P. Clopenthixol decanoate in schizophrenia. Curr Med Res Opin 1981;7:205–11.
3. Carney MWP. A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate. Pharmatherapeutica 1984;4:57–63.
4. Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. Ⅰ. A one-year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatr Scand 1980;61(suppl 279):10–29.
5. Dom R, DeMesmaecker L, Van den Broucke M, van Hest T, Baro F. A study with the long-acting thioxanthene derivative, cis(z)clopenthixol decanoate-sordinol depot. Acta Psychiatr Scand 1978;57:299–304.
6. Nazi HA. An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica 1986;4:555–60.
7. Szukalski B, Lipska B, Welbel L, Nurowska K. Serum levls and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology 1986;89:428–31.
8. Viswanathan R, Tajhkowa S. Clopenthixol decanoate in the treatment of chronic schizophrenic inpatients. Pharmatherapeutica 1982;3:93–9.
9. Bobon D, Troisfontaines B, Kempeneers J-L, Xhenseval B, Bourdouxhe S, Mirel J, Gilson H, Toussaint C, von Frenckell R, Pedersen V. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMPD scales. Acta Psychiatr Belg 1986;86:152–76.
10. Gravem A, Bugge a. Cis(z)-clopenthixol and clopenthixol in the treatment of acute psychosis and exacerbations of chronic psychoses. A double-blind clinical investigation. Acta Psychiatr Scand 1981;64(suppl 294):13–24.
11. Heikkila L, Laitinen J, Variainen H. Cis(z)-clopenthixol and haloperidol in chronic schizophrenic patients—a double-blind clinical multicentre investigation. Acta Psychiatr Scand 1981;64(suppl 294):30–8.
12. Koenig P, Seifert T, Eberhardt G. Findings with cis-z-clopenthixol in the treatment of acute mania and schizophrenia. Pharmacopsychiatry 1986;19:424–8.
13. Mann BS, Moslehuddin KS, Owen RT, Clayton AR, Rohatgi KK, Sud P, Vaddaki KS. Aclinical assessment of zuclopenthixol dihydrochloride (Clopixol tablets) in the treatment of psychotic illness. Pharmatherapeutica 1985;4:387–92.
14. Remvig J, Larsen H, Rask P, Skausig OB, Skov S, Stromgren LS. Zuclopenthixol and perphenazine in patients with acute psychotic states. Adouble-blind multicentre study. Pharmacopsychiatry 1987;20:147–54.
15. Amdisen A, Aaes-Jorgensen T, Thomsen NJ, Madsen VT, Nielsen MS. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology 1986;90:412–6.
16. Amdisen A, Nielsen MS, Dencker SJ, Fensbo C, Ahlfors UG, Gravem A, Baastrup PC, Bjerkenstedt L, Gunby B, Wiesel FA. Zuclopenthixol acetate in Viscoleo—a new drug formulation. An open Nordic multicentre study of zuclopenthixol acetate in Viscoleo in patients with acute psychoses including mania and exacerbation of chronic psychoses. Acta Psychiatr Scand 1987;75:99–107.
17. Balant LP, Balant-Gorgia AE, Eisele R, Reith B, Gex-Fabry M, Garrone G.Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. Pharmacopsychiatry 1989;22:250–4.
18. Bobon D, Debleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients—a randomized multicentre study. proceedings from the Symposium “New Strategies in the Treatment of Psychotic Patients,” 8th World Congress of Psychiatry, Athens, October 1989;13–19.
19. Bourdouxhe S, Mirel J, Denys W. Bobon D. Zuclopenthixol acetate and haloperidol in acute psychoses. Results of the AMDP subgroup in a multicentre Belgian study. Acte Psychiatr Belg 1987;87:236–44.
20. Chakravarti SK, Muthu A, Muthu PK, Naik P, Pinto RT. Zuclopenthixol acetate (5% in “Viscoleo”):single-dose treatment for acutely disturbed psychotic patients. Curr Med Res Opin 1990;12:55–65.
21. Fend I, Jochum W, Eberhardt G, König P. An open study of zuclopenthixol acetate in Viscoleo in patients with acute psychoses. Schizophr Res 1988;1::359–61.
22. Lowert AC, Rasmussen EM, Holm R, Almbjerg F, Calberg H, Joensen A, Nimb M, Baden H, Andersen E, Westergard T, Larsen H, Mayelund C. Acute psychotic disorders treated with 5% zuclopenthixol acetate in “Viscoleo”(Cisordinol-Acutard), a global assessment of the clinical effect: an open multi-centre study. Pharmatherapeutica 1989;5:380–6.
23. Matar AM, Abdel-Mawgoud M, Skoy S. Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial. J Clin Psychopharmacol 1990;10:283–6.
24. Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Elgen K, Brekke B, Fredslund-andersen K, Lindholm H, Lybeck I, Morawski R, Nummi K, Silfverhjelm H, Vartiainen H, Wiesel FA, Aarvold A. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatr Scand 1993;87:44–58.
25. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.
26. Overall JE, Klett CJ. Applied multivariate analysis. New York: McGraw-Hill, 1972.
27. Hollister LE, Overall JE, Kimbell I Jr, Pokorny A. Specific indications for different classes of phenothiazines. Arch Gen Psychiatry 1974;30:94–9.
28. Honigfeld G, Klett C. The nurses observation scale for inpatient evaluation (NOSIE): a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65–71.
29. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Esxtrapyramidal symptom rating seale. Can J Neurol Sci 1980;7:233.
30. Chouinard G, Ross-Chouinard A, Gauthier S, Annable L, Mercjer P. An extrapyramidal rating scale for idiopathic and neurolepticinduced parkinsonism and dyskinesia [abstr]. 14th CINP Congress. 1984:F13.
31. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8:21S–6S.
32. Gardos G, Cole JO, Salomon M, Schniebolk S. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987;144:895–902.
33. Lingjacrde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987;76(suppl 344):81–94.
34. 2-dopamine of Lundbeck Symposium “Modern Trends in the Treatment of Chronic Schizophrenia,” Fifth World Congress of Biological Psychiatry. Amsterdam: Excerpta Medica 1991;13–21.
35. Northeved H, Hojelse F. Repeated intramuscular injections of zuclopenthixol acetate and haloperidol. Presented at a symposium for Dutch psychiatrists. Copenhagen, Denmark, September 22, 1989.
36. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739–45.
37. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754–8.
38. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical respoonse: a therapeutic window relationship. Am J Psychiatry 1992;149:500–5.
39. Pope HG Jr, Lipinski JF, Cohen BM, Axelrod DT. “Schizoaffective disorder”: an invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder. Am J Psychiatry 1980;137:927–7.
40. Taylor MA, Abrams R. Manic-depressive illness and good prognosis schizophrenia. Am J Psychiatry 1975;132:741–2.
41. Tsuang MT, Dempsey GM. Long-tern outcome of major psychoses, Ⅱ: Schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1979;36:1302–4.